Shares in US biotech Replimune (Nasdaq: REPL) slumped around a third on Tuesday after US Food and Drug Administration (FDA) reviewers issued a harsh assessment of the company's latest bid to win ...

US biotech major Biogen (Nasdaq: BIIB) opened the large-cap neuroscience earnings run with second-quarter revenue of $2.74 ...

A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...

A European antibody-drug conjugate developer acquired by Eli Lilly in August 2023 for up to $600 million, whose lead Nectin-4 ADC, ETx-22, was subsequently deprioritized inside Lilly's dual-track ...

A clinical‑stage biopharma company based California, focused on therapies for CNS disorders. Founded by experts in psychiatry and neuroscience to target neural circuits causally linked to disease, the ...

UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty ...

ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...

US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug ...

US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...

Aurora’s stated regulatory strategy is to use emerging frameworks that allow grouping of multiple variants within a disease into a unified development and approval path. Near-term milestones are ...

Cambridge Antibody Technology is the latest firm to join the Pfizer-Gen network of alliances, which Pfizer initiated in 1995 to expand its biotechnology expertise. As a result, CAT has signed a ...